pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Abraxane
drug
save

paclitaxel albumin bound

Marketedupdated 6mo ago
by Celgene Corp
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • drugpaclitaxel36 co-mentions · 27 sources
  • drugSOR-00736 co-mentions · 27 sources
  • tagAdCom28 co-mentions · 25 sources
  • tagPMA Approval28 co-mentions · 25 sources
  • company$BSXBOSTON SCIENTIFIC CORP5 co-mentions · 5 sources
  • tagOncology3 co-mentions · 1 sources
  • companyBaxter Healthcare Corp1 co-mentions · 1 sources
  • companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 109 investigational indications.

indications

investigational
NSCLCBreast Cancer

all catalysts(0)

nothing on the calendar yet

Trials studying paclitaxel albumin bound

  • phase2An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.recruitingn=660
  • phase2A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)active not recruitingn=199
  • phase3Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Canceractive not recruitingn=579
  • phase3Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancernot yet recruitingn=198
  • phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)recruitingn=1,000
  • phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)recruitingn=1,123
  • phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).recruitingn=605
  • phase3A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)recruitingn=646

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 13, 2027
85 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

  • Jul 12, 2034patentUS 9511046*PED
  • Jan 12, 2034method-of-use (U-1434)US 9511046
  • Sep 4, 2032patentUS 9393318*PED
  • Sep 4, 2032patentUS 9597409*PED
  • Mar 4, 2032method-of-use (U-1290)US 9393318
  • Mar 4, 2032method-of-use (U-1290)US 9597409
  • Feb 13, 2027patentUS 8034375*PED85d
  • Aug 21, 2026patentUS 7758891*PED
  • Aug 21, 2026patentUS 8268348*PED
  • Aug 21, 2026patentUS 9101543*PED
  • Aug 13, 2026method-of-use (U-1290)US 8034375
  • Feb 21, 2026method-of-use (U-1434)US 7758891
  • Feb 21, 2026method-of-use (U-1290)US 8268348
  • Feb 21, 2026method-of-use (U-1434)US 9101543

News(10)

  • Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
    Faeth Therapeutics’ endometrial cancer prospect has cleared the phase 2 efficacy bar, emboldening the biotech to forge ahead with efforts to establish the oral therapy in a field dominated by injec…
    fiercebiotech · 13d ago
  • ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
    Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.
    fiercebiotech · 25d ago
  • Novocure hit by cyberattack exposing patient data
    Novocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that unauthorized access to some of its information systems exposed patient and emp…
    fiercebiotech · 2mo ago
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    stat · 5mo ago
  • Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies
    Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.
    onclive · 6mo ago
  • Five Under 5: Top Oncology Videos for the Week of 5/3
    The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
    onclive · 6mo ago
  • Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
    R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
    onclive · 6mo ago
  • Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
    Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.
    onclive · 6mo ago
  • Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
    Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.
    onclive · 6mo ago
  • Dr Sznol on Optimal Treatment Sequencing in Melanoma
    Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.
    onclive · 6mo ago
view all news mentions →
brand
Abraxane
generic
paclitaxel
MOA
Tubulin inhibitor
indication
Non-Small Cell Lung Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?